Beginning next month, patients utilizing the Foster light therapy, which is included on the Positive list, will gain access to the treatment without incurring additional costs from pharmacies. According to the Ministry of Health, the manufacturer responsible for the light therapy has formally communicated these changes to benefit patients. Under the new arrangement, recipients will only be responsible for the standard statutory prescription fee.
This updated coverage extends beyond the specific Foster product. The provisions also apply to other light therapies that utilize the same active components and are prescribed for the management of Chronic Obstructive Pulmonary Disease (COPD) within third-party care settings. The Ministry of Health confirmed that it intends to maintain and expand efforts aimed at improving the overall supply chain of light therapy.
Furthermore, the Ministry affirmed its commitment to implementing measures designed to reduce out-of-pocket expenses for patients. These ongoing initiatives are intended to minimize gaps in patient access to necessary treatments. The policy adjustments signal a focus on ensuring consistent and affordable care options for individuals managing respiratory conditions.
Topics: #light #therapy #foster
